Background: In winter 2024/2025, one of the most severe U.S. influenza epidemics since 2017, with 82 million illnesses and ~ 130,000 deaths, eclipsed a comparatively subdued SARS-CoV-2 wave (~ 20 million infections, ~540,000 hospitalizations, ~63,000 COVID-19 deaths), a hypothesis supported by existing CDC data and virological models.
Hypothesis: Influenza's robust interferon response might have contributed to suppression of SARS-CoV-2 replication, creating an antiviral environment that delayed COVID-19's winter surge.
Evidence: In vitro studies demonstrate influenza interference with SARS-CoV-2, reversible by oseltamivir, supporting this hypothesis. Thus, the decline in influenza activity in spring 2025 may have contributed to the observed increase in SARS-CoV-2 hospitalizations, driven by the NB.1.8.1 variant, a JN.1 derivative with enhanced transmissibility and reduced neutralization. Although this did not evolve into a pandemic-scale wave, the resultant burden on healthcare services was clinically meaningful. Alternative explanations, including behavioral changes and Omicron-induced herd immunity, are considered but less compelling.
Implication: The global health implications are critical: lapsed COVID-19 preparedness, limited surveillance, and low vaccine uptake threaten effective responses.
Recommandations: We advocate enhanced surveillance, adopting wastewater monitoring as demonstrated in the U.S., and integrated vaccination campaigns with combined influenza-COVID-19 vaccines, currently in phase III trials, to boost immunity. Resource allocation, informed by the 2024/2025 hospital overload, is essential to manage surges. This article underscores the need for global coordination to understand viral interference and prepare for shifting respiratory virus dynamics, offering actionable strategies to mitigate future epidemics, including those caused by other viruses.
Keywords: 2024/2025; Covid‐19; Influenza; SARS‐CoV‐2; viral interference.
© 2025 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.